Cambridge, MA – James Richard Porter, serving as President and CEO of Nuvalent, Inc. (NASDAQ:NUVL), completed the sale of 30,000 shares of the company’s Class A Common Stock on July 6, 2026. The transaction generated proceeds of approximately $3.71 million. These divestments were executed in accordance with a Rule 10b5-1 trading plan that Mr. Porter adopted on December 4, 2025. The timing of the sale coincides with the stock trading near its 52-week high of $123.83, a level reached after the stock delivered a 57% return over the preceding year.
Mr. Porter sold the 30,000 shares at a weighted average price of $123.72 per share, resulting in a total transaction value of $3,711,600. The execution occurred across multiple trades, with prices fluctuating between $123.66 and $123.78. Concurrent with the sale, Mr. Porter exercised options to acquire an equivalent 30,000 shares of Class A Common Stock. The exercise price for these options was set at $18.93 per share, representing a total acquisition cost of $567,900. The underlying shares were fully vested at the time of exercise.
Post-transaction, Mr. Porter’s direct holdings in Nuvalent’s Class A Common Stock stand at 324,879 shares. Additionally, he retains 118,686 derivative shares in the form of stock options. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors can access 12 additional InvestingPro Tips and comprehensive financial metrics for deeper analysis of NUVL’s investment potential.
Significant corporate developments are also underway. GSK announced a $10.6 billion agreement to acquire Nuvalent, Inc. The acquisition structure involves a tender offer for all outstanding shares at $124 per share. This offer represents a 40% premium to Nuvalent’s last closing price. The deal is designed to enhance GSK’s oncology assets, specifically by adding two late-stage drug candidates, zidesamtinib and neladalkib. Both candidates are currently under FDA review for the treatment of non-small cell lung cancer.
Market reactions to the acquisition news have prompted analyst adjustments. UBS downgraded Nuvalent’s stock rating to Neutral, lowering the price target to $124. Similarly, Bernstein downgraded Nuvalent to Market Perform, adjusting the price target to $124 due to the acquisition deal. Prior to the acquisition announcement, Bernstein had reiterated an Outperform rating with a $172 price target. Additionally, Leerink maintained an Outperform rating with a $165 price target after reviewing data from the ASCO conference. These developments reflect the significant impact of the GSK acquisition on Nuvalent’s market evaluations.
The stock closed at $123.80, reflecting a gain of $0.03 or 0.02%. After hours trading showed a decline to $123.65, down $0.15 or 0.12%. The recent price action highlights the volatility surrounding the acquisition announcement and executive trading activity.